RNAi Therapeutics Market (Covid-19) Impact and Analysis by 2027 | Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc.

The Insight Partners analysts forecasts the latest report on “RNAi Therapeutics Market (Covid-19) Impact and Analysis by 2027”, according to report; The RNAi Therapeutics Market report covers the overall and all-inclusive analysis of Market with all its factors that have an impact on market growth. This report is anchored on the thorough qualitative and quantitative assessment of the RNAi Therapeutics Market.

The study provides details such as the market share, Market Insights, Strategic Insights, Segmentation and key players in the RNAi Therapeutics Market.

Download Sample Report of RNAi Therapeutics Market Report @ https://www.theinsightpartners.com/sample/TIPRE00007157/?openpr-10225

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The RNAi therapeutics market was valued at US$ 618.79 million in 2019and is projected to reach US$ 1,209.29 millionby 2027; it is expected to grow at a CAGR of 8.8%from 2020to 2027.

Some of the Major Market Players Are:

Alnylam Pharmaceuticals, Inc.
Sanofi
Olix Pharmaceuticals, Inc.
Glaxosmithkline Plc.
Benitec Biopharma
Arbutus Biopharma Corporation
Silence Therapeutics
Rexahn Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc
Quark

Market Insights

Growing Investments in RNAi Therapies

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of the outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in September 2018, Curamir Therapeutics, Inc. received initial financial aid of US$ 10 million from Delos Capital to develop miRNA-based drugs for chemotherapy-resistant cancer. Also, in April 2019, Alnylam Pharmaceuticals Inc. announced its strategic partnership with Regeneron Pharmaceuticals to discover and commercialize RNAi therapeutic platform for the treatment of diseases associated with eye, central nervous system, and liver. The companies have invested about US$ 1 billion in the collaboration. Furthermore, in January 2020, Dicerna Pharmaceuticals, Inc. and Novo Nordisk collaborated to develop RNAi therapies for the treatment of liver diseases and cardiometabolic disorders. Dicerna Pharmaceuticals, Inc. received an upfront payment of ~US$ 175 million from Novo Nordisk for the initiation of the project. Furthermore, according to the terms in partnership, Dicerna Pharmaceuticals, Inc. will receive nearly US$ 25 million annually from Novo Nordisk for the first three years for the development of the product. Such investments help biotech and pharma companies not only launch new products but also increase the number of approved products. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received an approval from the US Food and Drug Administration (FDA) for its Onpattro infusion therapy used for the treatment of peripheral nerve disease (polyneuropathy). The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

Molecule Type-Based Insights

Based on molecule type, the RNAi therapeutics market is segmented into small interfering RNAs (siRNA) and microRNA (miRNA). The small interfering RNAs (siRNA) segment held a larger share of the market in 2019. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Further, the MicroRNA (miRNA) segment is expected to register higher CAGR in the global RNAi therapeutics market during the forecast period.

Application-Based Insights

Based on application, the RNAi therapeutics market is segmentedinto oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others. In 2019, the oncology segment accounted for the largest share ofthe global RNAi therapeutics market owing to increasing preference for RNAi therapies for the treatment of cancer. Moreover, growing number of research collaborations in the field of oncology are also projected to drive the segment growth by 2027. However, cardiovascular disorders segment is estimated to register the highest CAGR in the market during the forecast period.

Route of Administration-Based Insights

Based on route of administration, the RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intradermal injections, intraperitoneal injections, and others. In 2019, the pulmonary delivery segment accounted for the largest share of the global RNAi therapeutics market. However, intravenous injections segment is estimated to register the highest CAGR in the market during the forecast period. Significant number or product launches and higher adoption of intravenous injection are likely to have a positive impact on the segment growth.

End User-Based Insights

Based on end user, the RNAi therapeutics market is further segmented into research and academic laboratories, hospitals, and diagnostic laboratories. The research and academic laboratories segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

Strategic Insights

Product launches and expansion strategies are commonly adopted by the companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the RNAi therapeutics market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.

By Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

By Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

By Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

By End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

The report analyses factors affecting the RNAi Therapeutics Market from further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the RNAi Therapeutics Market in these regions.

Moreover, the report entails the estimate and analysis for the RNAi Therapeutics Market on a global as well as regional level. The study provides historical data as well as the trending features and future predictions of the market growth. Further, the report encompasses drivers and restraints for the RNAi Therapeutics Market growth along with its impact on the overall market development. In addition, the report provides an analysis of the accessible avenues in the market on a global level.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global RNAi Therapeutics Market based on various segments. It also provides market size and forecast estimates from the year 2018 to 2027 with respect to five major regions. The RNAi Therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

Promising Regions & Countries Mentioned in The RNAi Therapeutics Market Report:
• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Major Features of RNAi Therapeutics Market Report:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global RNAi Therapeutics market
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global RNAi Therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution.

Purchase a copy of RNAi Therapeutics Market research report @ https://www.theinsightpartners.com/buy/TIPRE00007157/?openpr-10225

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

This release was published on openPR.